Literature DB >> 22846941

Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration.

Bryan A Cotton1, John A Harvin, Vadim Kostousouv, Kristin M Minei, Zayde A Radwan, Herbert Schöchl, Charles E Wade, John B Holcomb, Nena Matijevic.   

Abstract

BACKGROUND: Hyperfibrinolysis (HF) has been reported to occur in a range of 2% to 34% of trauma patients. Using rapid thromboelastography (r-TEG), we hypothesized that HF is (1) rarely present at admission on patients with severe injury and (2) associated with crystalloid hemodilution. To further strengthen this hypothesis, we created an in vitro hemodilution model to improve our mechanistic understanding of the early HF.
METHODS: The trauma registry was queried for patients who were our highest-level trauma activations and admitted directly from the scene (October 2009-October 2010). HF was defined as more than 7.5% amplitude reduction 30 minutes after maximal amplitude (LY30). Using r-TEG, we then created an in vitro hemodilution model (0.9% NS) with and without tissue injury (addition of tissue factor and tissue plasminogen activator) to identify crystalloid volumes and injury needed to achieve specific LY30 values.
RESULTS: Admission r-TEG values were captured on 1996 consecutive admissions. Only 41 patients (2%) had HF at admission r-TEG. The groups were similar in demographics. Compared with patients without HF, the HF group had more prehospital crystalloid (1.5 vs. 0.5 L), higher median Injury Severity Score (25 vs. 16), greater admission base deficit (20 vs. 2), and higher mortality (76% vs. 10%); all p < 0.001. Controlling for Injury Severity Score and base deficit on arrival, prehospital fluid was associated with a significant increase in likelihood of HF. In fact, each additional liter of crystalloid was associated with a 15% increased odds of HF. The in vitro model found that hemodilution to 15% of baseline and tissue factor + tissue plasminogen activator was required to achieve an LY30 of 50%.
CONCLUSION: Although uncommon immediately after injury, HF is associated with prehospital crystalloid administration and shock at admission and is highly lethal. Our in vitro model confirms that tissue injury and significant crystalloid hemodilution result in severe and immediate HF.

Entities:  

Mesh:

Year:  2012        PMID: 22846941     DOI: 10.1097/TA.0b013e31825c1234

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  69 in total

1.  Effect of damage control laparotomy on major abdominal complications and lengths of stay: A propensity score matching and Bayesian analysis.

Authors:  John A Harvin; John P Sharpe; Martin A Croce; Michael D Goodman; Timothy A Pritts; Elizabeth D Dauer; Benjamin J Moran; Rachel D Rodriguez; Ben L Zarzaur; Laura A Kreiner; Jeffrey A Claridge; John B Holcomb
Journal:  J Trauma Acute Care Surg       Date:  2019-08       Impact factor: 3.313

2.  Better understanding the utilization of damage control laparotomy: A multi-institutional quality improvement project.

Authors:  John A Harvin; John P Sharpe; Martin A Croce; Michael D Goodman; Timothy A Pritts; Elizabeth D Dauer; Benjamin J Moran; Rachel D Rodriguez; Ben L Zarzaur; Laura A Kreiner; Jeffrey A Claridge; John B Holcomb
Journal:  J Trauma Acute Care Surg       Date:  2019-07       Impact factor: 3.313

3.  [Uncritical use of tranexamic acid in trauma patients : Do no further harm!]

Authors:  M Maegele
Journal:  Unfallchirurg       Date:  2016-11       Impact factor: 1.000

Review 4.  Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid.

Authors:  Ernest E Moore; Hunter B Moore; Eduardo Gonzalez; Michael P Chapman; Kirk C Hansen; Angela Sauaia; Christopher C Silliman; Anirban Banerjee
Journal:  J Trauma Acute Care Surg       Date:  2015-06       Impact factor: 3.313

5.  Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient.

Authors:  Ernest E Moore; Hunter B Moore; Eduardo Gonzalez; Angela Sauaia; Anirban Banerjee; Christopher C Silliman
Journal:  Transfusion       Date:  2016-04       Impact factor: 3.157

6.  Post-translational oxidative modification of fibrinogen is associated with coagulopathy after traumatic injury.

Authors:  Nathan J White; Yi Wang; Xiaoyun Fu; Jessica C Cardenas; Erika J Martin; Donald F Brophy; Charles E Wade; Xu Wang; Alexander E St John; Esther B Lim; Susan A Stern; Kevin R Ward; José A López; Dominic Chung
Journal:  Free Radic Biol Med       Date:  2016-04-20       Impact factor: 7.376

7.  Plasma is the physiologic buffer of tissue plasminogen activator-mediated fibrinolysis: rationale for plasma-first resuscitation after life-threatening hemorrhage.

Authors:  Hunter B Moore; Ernest E Moore; Eduardo Gonzalez; Gregory Wiener; Michael P Chapman; Monika Dzieciatkowska; Angela Sauaia; Anirban Banerjee; Kirk C Hansen; Christopher Silliman
Journal:  J Am Coll Surg       Date:  2015-03-31       Impact factor: 6.113

8.  Pre-trauma center red blood cell transfusion is associated with improved early outcomes in air medical trauma patients.

Authors:  Joshua B Brown; Jason L Sperry; Anisleidy Fombona; Timothy R Billiar; Andrew B Peitzman; Francis X Guyette
Journal:  J Am Coll Surg       Date:  2015-01-24       Impact factor: 6.113

9.  Decreasing the Use of Damage Control Laparotomy in Trauma: A Quality Improvement Project.

Authors:  John A Harvin; Lillian S Kao; Mike K Liang; Sasha D Adams; Michelle K McNutt; Joseph D Love; Laura J Moore; Charles E Wade; Bryan A Cotton; John B Holcomb
Journal:  J Am Coll Surg       Date:  2017-04-23       Impact factor: 6.113

10.  Systemic hyperfibrinolysis after trauma: a pilot study of targeted proteomic analysis of superposed mechanisms in patient plasma.

Authors:  Anirban Banerjee; Christopher C Silliman; Ernest E Moore; Monika Dzieciatkowska; Marguerite Kelher; Angela Sauaia; Kenneth Jones; Michael P Chapman; Eduardo Gonzalez; Hunter B Moore; Angelo D'Alessandro; Erik Peltz; Benjamin E Huebner; Peter Einerson; James Chandler; Arsen Ghasabayan; Kirk Hansen
Journal:  J Trauma Acute Care Surg       Date:  2018-06       Impact factor: 3.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.